What is INSIGHTEC?
Headquartered in Haifa, Israel, and established in 1999, INSIGHTEC is a specialized medical device manufacturer focused on the development of incisionless magnetic resonance-guided ultrasound solutions. The company operates at the intersection of advanced imaging and therapeutic intervention, providing clinicians with precise, non-invasive tools to treat complex medical conditions. By integrating real-time MRI guidance with focused ultrasound energy, INSIGHTEC enables highly accurate procedures that minimize patient trauma and recovery time. Its market position is defined by a commitment to innovation in neurosurgery and oncology, supported by a robust portfolio of intellectual property and strategic partnerships with global healthcare technology leaders.
How much funding has INSIGHTEC raised?
INSIGHTEC has raised a total of $784.9M across 8 funding rounds:
Series B
$15M
Series C
$30.9M
Series D
$59M
Series E
$150M
Other Financing Round
$150M
Debt
$200M
Private Equity
$150M
Series B (2009): $15M led by Elbit Imaging Ltd.
Series C (2012): $30.9M supported by GE Healthcare
Series D (2014): $59M featuring York Capital, GE Healthcare, Elbit Imaging Ltd., and Boston MedTech Advisors
Series E (2017): $150M backed by Focus Holdings, KDT, GE Healthcare, Elbit Imaging Ltd., and York Capital
Other Financing Round (2020): $150M with participation from Koch
Debt (2022): $200M led by Perceptive Advisors and The Community Fund Vc
Private Equity (2024): $150M supported by Baillie Gifford, Ally Bridge Group, Nexus NeuroTech Ventures, and Fidelity
Key Investors in INSIGHTEC
Baillie Gifford
An investment management firm founded in 1908 in Edinburgh, specializing in long-term investment advice and asset management.
Ally Bridge Group
A global healthcare investment firm managing over $6 billion in transactions, focused on high-impact life science innovation and private equity strategies.
Nexus NeuroTech Ventures
A specialized venture firm founded in 2023, dedicated to accelerating breakthrough medical technologies for neurological and psychiatric disorders.
What's next for INSIGHTEC?
With the successful closure of this latest financing round, INSIGHTEC is poised to enter a new phase of commercial expansion and clinical adoption. The strategic focus will likely shift toward scaling the deployment of its ultrasound platforms across international markets and expanding the scope of its FDA-cleared indications. By utilizing the recent capital injection, the company aims to enhance its digital infrastructure and data analytics capabilities, which are essential for optimizing patient outcomes and streamlining clinical workflows. As the healthcare industry increasingly pivots toward minimally invasive procedures, INSIGHTEC's technology is uniquely positioned to capture significant market share, driving long-term value for its stakeholders and improving the standard of care for patients worldwide.
See full INSIGHTEC company page
